NGEN stock forecast, quote, news & analysis
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions... Show more
Why NervGen Pharma (NGEN) Stock Is Down -24% in the Last 30 Days
Key Takeaways
- NervGen Pharma (NGEN) declined roughly 24% over the last 30 days, falling from about $1.94 to $1.48 as of late October 2026.
- The slide extended a retreat from the stock's late-August peak near $2.34 and reflected profit-taking, a disclosed financial restatement, and funding-related concerns.
- Over the trailing quarter, shares are down approximately 10%, marked by elevated volatility around clinical and financing milestones.
- The investment case centers on NVG-291, the company's lead candidate for spinal cord injury, which has advanced into the Phase 3 RESTORE registrational study.
- As a pre-revenue, clinical-stage biotech, NGEN trades primarily on clinical progress, regulatory news, and sentiment rather than near-term fundamentals.
- Key catalysts ahead include RESTORE enrollment progress, additional data updates, and indication-expansion news, balanced against operating losses and future funding needs.
- For more detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Readers interested in automated strategies can also explore Trending AI Robots on Tickeron.
NervGen Pharma (NGEN) Company Overview and Market Position
NervGen Pharma Corp. is a Vancouver-based, clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, is a subcutaneously administered peptide designed to promote nervous system repair by targeting mechanisms that inhibit regeneration after injury.
The company has no approved products or meaningful revenue. NVG-291 has received Fast Track designation from the U.S. Food and Drug Administration and Orphan Drug designation from the European Medicines Agency for spinal cord injury. NervGen also holds a licensing agreement with Case Western Reserve University covering its underlying technology, and it is advancing a second candidate, NVG-300, in earlier stages of development. Investors follow NGEN because its clinical program targets a condition with significant unmet medical need and no approved pharmacologic treatment, a profile that can generate substantial share-price moves on milestone news.
NervGen Pharma (NGEN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NGEN declined approximately 24%, from a closing price of about $1.94 to $1.48. The move was broadly directional rather than a single-day event, with the stock stepping lower through October and briefly touching levels near its 52-week low.
Over the trailing quarter, the picture is more nuanced. The stock traded near $1.60 to $1.64 in late July, rallied to roughly $2.34 in late August, and then gave back those gains, ending the period around $1.48 for a net decline of roughly 10%. This pattern highlights the stock's sensitivity to news flow: sharp rallies tied to clinical and financing updates have been followed by equally sharp retracements as catalysts pass and attention shifts to longer-dated milestones.
What Drove NGEN Stock Price in the Last 30 Days
Several verified factors contributed to the recent decline. First, on September 25, 2026, NervGen announced it would restate its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim statements for the quarter ended June 30, 2026, reflecting non-cash accounting adjustments. Restatement disclosures often weigh on investor confidence, particularly for pre-revenue companies.
Second, the stock entered the period after a sharp late-August rally, leaving it vulnerable to profit-taking once the immediate catalysts faded. The company's inaugural R&D Day on September 30, 2026, provided scientific detail but did not reverse the selling pressure. Third, funding-related concerns persisted: NervGen completed a US$60 million public offering earlier in 2026 and later established a US$50 million at-the-market facility, while continuing to report operating losses, including a net loss of C$29.2 million in the second quarter. For a company that relies on equity financing to fund a multi-year Phase 3 program, dilution risk remains a recurring theme in the stock's performance.
What Drove NGEN Stock Performance Over the Last Quarter
The quarterly trend reflects a cooling of the enthusiasm that followed NervGen's Nasdaq listing and its earlier clinical data. During the quarter, the company reported positive independent biomechanical gait analyses from its CONNECT SCI study, reiterated FDA alignment on the RESTORE Phase 3 design, and disclosed funding sufficient to reach the anticipated topline readout in the first half of 2028. Those updates helped fuel the August advance.
However, the broader narrative has shifted toward execution over a longer timeline. With the Phase 3 RESTORE study expected to complete enrollment in the second half of 2027 and topline data not anticipated until the first half of 2028, near-term share-price catalysts are limited. The financial restatement and ongoing financing needs compounded this sentiment shift, contributing to the stock's retreat from its quarterly high toward its recent lows.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's automated trading strategies. While Tickeron offers hundreds of AI-powered trading bots across thousands of tickers, only the top-performing and most relevant bots are featured in this section, helping users filter a large universe of options. The bots differ in strategy, holding timeframe, and performance metrics, so the page serves as a starting point for investors evaluating systematic approaches rather than a one-size-fits-all recommendation. Readers seeking data-driven trading ideas may find it useful to browse the section and review each bot's objectives and track record.
NGEN Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important drivers for NGEN are clinical and regulatory. Progress on RESTORE site activation and patient enrollment will be closely watched, along with any updates on the subacute SCI cohort and the company's planned indication-expansion priorities. Updates on the financial restatement and any subsequent financing activity will also matter, given the company's reliance on equity capital to fund development through the anticipated 2028 topline readout. Because NGEN is pre-revenue, its share price is likely to remain highly sensitive to data announcements, regulatory communications, and broader sentiment toward speculative small-cap biotechnology. These factors should be monitored in the context of the company's disclosed timeline and funding position.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NGEN in -3.65% downward trend, falling for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NGEN declined for three days, in 262 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for NGEN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NGEN's RSI Oscillator exited the oversold zone, 28 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for NGEN just turned positive on November 06, 2026. Looking at past instances where NGEN's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NGEN advanced for three days, in 207 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.277) is normal, around the industry mean (3.498). P/E Ratio (-1.684) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. NGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology